PharmTech Drug Digest 11.20
News|Articles|August 29, 2013

PPD Acquires Acurian

Pharmaceutical Product Development has acquired patient-recruitment contractor Acurian.

Pharmaceutical Product Development (PPD), has acquired Acurian, a service provider of clinical trial patient enrollment and retention solutions for the life sciences industry.

Providing analytics-driven services to large and mid-sized pharmaceutical companies, Acurian manages the patient recruitment, enrollment, and retention. The company uses software analytics to customize approaches for recruiting patients for a customer’s clinical trial.

Acurian will continue to operate under its own name as a separate business unit with its existing management team led by Rick Malcolm, who has served as Acurian’s CEO since 2005.

Source:

Pharmaceutical Product Development


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.